JP2020007333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020007333A5 JP2020007333A5 JP2019153406A JP2019153406A JP2020007333A5 JP 2020007333 A5 JP2020007333 A5 JP 2020007333A5 JP 2019153406 A JP2019153406 A JP 2019153406A JP 2019153406 A JP2019153406 A JP 2019153406A JP 2020007333 A5 JP2020007333 A5 JP 2020007333A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- signal
- glyx
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 210000004556 brain Anatomy 0.000 claims 4
- 230000007177 brain activity Effects 0.000 claims 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims 4
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915835P | 2013-12-13 | 2013-12-13 | |
| US61/915,835 | 2013-12-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538538A Division JP2017500306A (ja) | 2013-12-13 | 2014-12-15 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020007333A JP2020007333A (ja) | 2020-01-16 |
| JP2020007333A5 true JP2020007333A5 (enExample) | 2020-07-27 |
Family
ID=53371976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538538A Pending JP2017500306A (ja) | 2013-12-13 | 2014-12-15 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
| JP2019153406A Pending JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538538A Pending JP2017500306A (ja) | 2013-12-13 | 2014-12-15 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160345855A1 (enExample) |
| EP (2) | EP3721799A1 (enExample) |
| JP (2) | JP2017500306A (enExample) |
| CN (2) | CN106102762A (enExample) |
| AU (2) | AU2014361822A1 (enExample) |
| CA (1) | CA2933372A1 (enExample) |
| IL (2) | IL246148A0 (enExample) |
| MX (1) | MX2016007716A (enExample) |
| WO (1) | WO2015089503A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362080A1 (en) * | 2015-10-16 | 2018-08-22 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| CN113557028A (zh) * | 2019-01-11 | 2021-10-26 | 诺雷克斯股份有限公司 | 雷帕替奈的盐和晶型 |
| CN110123342B (zh) * | 2019-04-17 | 2021-06-08 | 西北大学 | 一种基于脑电波的网瘾检测方法及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US20050273017A1 (en) * | 2004-03-26 | 2005-12-08 | Evian Gordon | Collective brain measurement system and method |
| WO2007123799A2 (en) * | 2006-04-03 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Assessing subject's reactivity to psychological stress using fmri |
| CA2659099A1 (en) * | 2006-06-15 | 2007-12-21 | Mars, Incorporated | Use of cocoa flavanols and procyanidins to improve executive cognitive and cerebral blood flow |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| HRP20140784T1 (hr) * | 2009-10-05 | 2014-10-10 | Northwestern University | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija |
| BR112013027554A2 (pt) * | 2011-04-27 | 2016-09-06 | Univ Northwestern | "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" |
| JP2015505314A (ja) * | 2012-01-09 | 2015-02-19 | 武田薬品工業株式会社 | アルツハイマー病を治療する方法及び医薬品 |
-
2014
- 2014-12-15 US US15/104,223 patent/US20160345855A1/en not_active Abandoned
- 2014-12-15 EP EP20174673.2A patent/EP3721799A1/en not_active Withdrawn
- 2014-12-15 EP EP14870211.1A patent/EP3079579A4/en not_active Withdrawn
- 2014-12-15 CN CN201480068036.1A patent/CN106102762A/zh active Pending
- 2014-12-15 MX MX2016007716A patent/MX2016007716A/es unknown
- 2014-12-15 CN CN202010314939.0A patent/CN111920412A/zh active Pending
- 2014-12-15 JP JP2016538538A patent/JP2017500306A/ja active Pending
- 2014-12-15 WO PCT/US2014/070340 patent/WO2015089503A2/en not_active Ceased
- 2014-12-15 CA CA2933372A patent/CA2933372A1/en not_active Abandoned
- 2014-12-15 AU AU2014361822A patent/AU2014361822A1/en not_active Abandoned
-
2016
- 2016-06-09 IL IL246148A patent/IL246148A0/en unknown
-
2019
- 2019-08-26 JP JP2019153406A patent/JP2020007333A/ja active Pending
- 2019-11-13 AU AU2019264583A patent/AU2019264583A1/en not_active Abandoned
-
2020
- 2020-08-02 IL IL276431A patent/IL276431A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cantone et al. | Cortical plasticity in depression: a neurochemical perspective from transcranial magnetic stimulation | |
| Young et al. | Changes in functional connectivity correlate with behavioral gains in stroke patients after therapy using a brain-computer interface device | |
| Lanza et al. | Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation | |
| Gao et al. | Effects of voluntary locomotion and calcitonin gene-related peptide on the dynamics of single dural vessels in awake mice | |
| Zhou et al. | Current evidence, clinical applications, and future directions of transcranial magnetic stimulation as a treatment for ischemic stroke | |
| Koszewicz et al. | The characteristics of autonomic nervous system disorders in burning mouth syndrome and Parkinson disease | |
| Atagün et al. | Decrease of event-related delta oscillations in euthymic patients with bipolar disorder | |
| JP2020007333A5 (enExample) | ||
| Lee et al. | Targeting neural synchrony deficits is sufficient to improve cognition in a schizophrenia-related neurodevelopmental model | |
| Opie et al. | Motor cortex plasticity induced by theta burst stimulation is impaired in patients with obstructive sleep apnoea | |
| Beynel et al. | What saccadic eye movements tell us about TMS-induced neuromodulation of the DLPFC and mood changes: a pilot study in bipolar disorders | |
| Elvsåshagen et al. | Evidence for impaired neocortical synaptic plasticity in bipolar II disorder | |
| Abraham et al. | Fatigue in motor neuron diseases | |
| Keplinger et al. | Effective local anaesthetic volumes for sciatic nerve blockade: a clinical evaluation of the ED99 | |
| André et al. | Rapid eye movement sleep, neurodegeneration, and amyloid deposition in aging | |
| Wang et al. | Neuroprotective effect of microglia against impairments of auditory steady-state response induced by anti-P IgG from SLE patients in naïve mice | |
| Avenali et al. | Clinical and electrophysiological outcome measures of patients with post-infectious neurological syndromes related to COVID-19 treated with intensive neurorehabilitation | |
| Benuzzi et al. | Recovery from emotion recognition impairment after temporal lobectomy | |
| D’Rozario et al. | Region-specific changes in brain activity and memory after continuous positive airway pressure therapy in obstructive sleep apnea: a pilot high-density electroencephalography study | |
| Kawashima et al. | Differences in dopaminergic modulation to motor cortical plasticity between Parkinson's disease and multiple system atrophy | |
| Nicoletti et al. | Treatment with dimethyl fumarate enhances cholinergic transmission in multiple sclerosis | |
| Mathur et al. | Coma, disorders of consciousness, and brain death | |
| Li et al. | Aberrant auditory steady-state response of awake mice induced by chronic interferon-α treatment | |
| Lucey | Sleep Alterations and Cognitive Decline | |
| Pinkhardt et al. | The combination of dopa-responsive parkinsonian syndrome and motor neuron disease |